老實說，台灣能從一開始前年十二月的武漢病毒、去年十月的英國變種病毒、十二月的南非變種病毒、今年一月的巴西變種病毒、三月的印度變種病毒，一路守到現在才出現二級防疫階段的社區感染，已經很厲害了。
國民黨的王八蛋們要是敢在這時扯CDC後腿，就拿「社區感染破口都在藍營執政縣市」砸回去。（心胸狹窄者冷笑
雖然已經有針對疫苗混打的研究了，但在現實中，各國政府對疫苗的選擇及施打仍受限於經費與供給量能。
＂Complicating both questions are the different technologies being used in the world’s armory of vaccines. Shots that use an inactivated virus to stimulate the immune system might perform differently from others that use messenger RNA, a molecule that directs cells to make antibodies against the virus. Little is known about the risk of side effects from multiple doses.
Governments considering booster programs also face logistical hurdles, such as whether to vaccinate everyone or just the elderly and vulnerable.＂
莫德納申請完整核可使用。
「目前莫德納疫苗在美國只取得緊急使用授權（EUA），這是繼輝瑞之後第二家尋求完全批准的疫苗製造商。」
莫德納聲明:
[“We thank Taiwan for their support in securing this new agreement to supply in 2022 and 2023 our mRNA COVID-19 vaccine and our updated variant booster candidate, if approved,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We remain committed to making our vaccine available around the world.” ]
莫德納提出生物製品許可申請(BLA)，FDA在審視安全性時也注意到12-17之間的青少年預防作用和成人組有相近效果。另一家輝瑞也是提出BLA申請了。
https://www.axios.com/moderna-coronavirus-vaccine-fda-6711dc5e-bcd5-4d20-8daf-807f13df0850.html